Long-term outcome of the unrestricted use of everolimus-eluting stents compared to sirolimus-eluting stents and paclitaxel-eluting stents in diabetic patients: the Bern-Rotterdam diabetes cohort study.

MLA

Simsek, C., et al. “Long-Term Outcome of the Unrestricted Use of Everolimus-Eluting Stents Compared to Sirolimus-Eluting Stents and Paclitaxel-Eluting Stents in Diabetic Patients: The Bern-Rotterdam Diabetes Cohort Study.” International Journal of Cardiology, vol. 170, no. 1, Dec. 2013, pp. 36–42. EBSCOhost, https://doi.org/10.1016/j.ijcard.2013.10.006.

APA

Simsek, C., Räber, L., Magro, M., Boersma, E., Onuma, Y., Stefanini, G. G., Zanchin, T., Kalesan, B., Wenaweser, P., Jüni, P., van Geuns, R. J., van Domburg, R. T., Windecker, S., & Serruys, P. W. J. C. (2013). Long-term outcome of the unrestricted use of everolimus-eluting stents compared to sirolimus-eluting stents and paclitaxel-eluting stents in diabetic patients: the Bern-Rotterdam diabetes cohort study. International Journal of Cardiology, 170(1), 36–42. https://doi.org/10.1016/j.ijcard.2013.10.006

Chicago

Simsek, C, L Räber, M Magro, E Boersma, Y Onuma, G G Stefanini, T Zanchin, et al. 2013. “Long-Term Outcome of the Unrestricted Use of Everolimus-Eluting Stents Compared to Sirolimus-Eluting Stents and Paclitaxel-Eluting Stents in Diabetic Patients: The Bern-Rotterdam Diabetes Cohort Study.” International Journal of Cardiology 170 (1): 36–42. doi:10.1016/j.ijcard.2013.10.006.